Compass Pathways Plc ADR (CMPS)

$5.10 -0.04 (-0.78%)
Market Cap 498.89M
Revenue (ttm) 0.00
Net Income (ttm) -155.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.19
Volume 862,000
Avg Vol 1,956,414
Day's Range N/A - N/A
Shares Out 95.94M
Stochastic %K 60%
Beta 2.17
Analysts Strong Sell
Price Target $14.90

Company Profile

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incor...

Industry: Medical Care Facilities
Sector: Healthcare
Address:
33 Broadwick Street, London, United Kingdom
Tpeets101
Tpeets101 Sep. 17 at 12:24 AM
$CMPS this will ten bucks one morning when we wake up! 🚀
0 · Reply
angelinvesting369
angelinvesting369 Sep. 16 at 9:14 PM
$QNRX 💩 vs $CMPS 🍄 🍆 💦 today's antidepressants have awful side effects like WEIGHT GAIN and IMPOTENCE. Psychedelics do not. Compass is only $500M mkt cap and the only psychedelic well into phase 3 trials. Glta
0 · Reply
angelinvesting369
angelinvesting369 Sep. 16 at 9:12 PM
$QNRX is a meme vs $CMPS 🍄 which is going to disrupt the $20B antidepressants industry
0 · Reply
Ramirami43
Ramirami43 Sep. 16 at 6:26 PM
$CMPS 8 before December ☝️
0 · Reply
nikstradamus
nikstradamus Sep. 16 at 2:45 PM
$CMPS Management should be dropping good news about the meeting with the FDA soon. Let’s hope they get that voucher https://www.fda.gov/industry/commissioners-national-priority-voucher-cnpv-pilot-program?utm_campaign=pharmalittle&utm_medium=email&_hsenc=p2ANqtz-9Y-yJB_9CC7EtqGvbEGYWqczmew0Ng_s7zwvZ25D3rUbviRO0dMlj-B6uFfaXPcmevkg8BNrcvDnzDA4CCDY1TLougJg&_hsmi=380780542&utm_content=380780542&utm_source=hs_email
1 · Reply
ClownThePoet
ClownThePoet Sep. 16 at 2:42 PM
$CMPS HOW CAN U BE BEARISH
0 · Reply
ClownThePoet
ClownThePoet Sep. 16 at 2:07 PM
$CMPS
0 · Reply
angelinvesting369
angelinvesting369 Sep. 16 at 12:58 PM
$TSLA $CMPS
0 · Reply
angelinvesting369
angelinvesting369 Sep. 16 at 12:57 PM
$TSLA $CMPS 🤖 will be the biggest industry in the 🌍 and 🍄 will disrupt the $20B antidepressant industry iykyk
0 · Reply
zmanx
zmanx Sep. 16 at 5:42 AM
$CMPS all set for Q4
0 · Reply
Latest News on CMPS
COMPASS Pathways Plc (CMPS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 2:03 PM EDT - 7 days ago

COMPASS Pathways Plc (CMPS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

COMPASS Pathways Plc (CMPS) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 4, 2025, 4:56 AM EDT - 12 days ago

COMPASS Pathways Plc (CMPS) Presents At Cantor Global Healthcare Conference 2025 Transcript

Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder

Sep 2, 2025, 6:30 AM EDT - 14 days ago

Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder

Compass Pathways to Participate in Four Investor Conferences in September

Aug 27, 2025, 6:30 AM EDT - 20 days ago

Compass Pathways to Participate in Four Investor Conferences in September

Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA

Aug 5, 2025, 6:30 AM EDT - 6 weeks ago

Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA

COMPASS Pathways plc (CMPS) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 10:32 AM EDT - 6 weeks ago

COMPASS Pathways plc (CMPS) Q2 2025 Earnings Call Transcript

Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights

Jul 31, 2025, 6:30 AM EDT - 6 weeks ago

Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights

Compass Pathways Appoints Justin Gover to Board of Directors

Jul 29, 2025, 6:30 AM EDT - 7 weeks ago

Compass Pathways Appoints Justin Gover to Board of Directors

Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

Jul 22, 2025, 6:30 AM EDT - 2 months ago

Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET

Jul 10, 2025, 4:00 PM EDT - 2 months ago

Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET

Compass Pathways Stock: Downgrading To Hold On Released TRD Results With COMP360

Jun 24, 2025, 2:47 PM EDT - 3 months ago

Compass Pathways Stock: Downgrading To Hold On Released TRD Results With COMP360

Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Jun 23, 2025, 8:25 AM EDT - 3 months ago

Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session

VZLA

Compass Pathways stock slip as psilocybin depression trial falls short of expectations

Jun 23, 2025, 8:12 AM EDT - 3 months ago

Compass Pathways stock slip as psilocybin depression trial falls short of expectations

Compass Pathways' depression drug succeeds late-stage trial

Jun 23, 2025, 6:48 AM EDT - 3 months ago

Compass Pathways' depression drug succeeds late-stage trial

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Jun 23, 2025, 6:30 AM EDT - 3 months ago

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 14, 2025, 6:30 AM EDT - 4 months ago

Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:14 AM EDT - 4 months ago

COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 6:30 AM EDT - 4 months ago

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

Apr 29, 2025, 6:30 AM EDT - 5 months ago

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

Apr 28, 2025, 6:30 AM EDT - 5 months ago

Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Apr 22, 2025, 6:00 AM EDT - 5 months ago

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

This Is a Test From GlobeNewswire

Mar 28, 2025, 5:01 PM EDT - 6 months ago

This Is a Test From GlobeNewswire

ALVO

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Mar 26, 2025, 6:30 AM EDT - 6 months ago

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Mar 18, 2025, 6:30 AM EDT - 6 months ago

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways to Participate in Stifel Virtual CNS Forum

Mar 11, 2025, 6:30 AM EDT - 6 months ago

Compass Pathways to Participate in Stifel Virtual CNS Forum

Compass Pathways: Betting On The Future Of Psilocybin Therapy

Feb 28, 2025, 5:08 PM EST - 7 months ago

Compass Pathways: Betting On The Future Of Psilocybin Therapy

Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says

Feb 27, 2025, 4:02 PM EST - 7 months ago

Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says

COMPASS Pathways plc (CMPS) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:41 AM EST - 7 months ago

COMPASS Pathways plc (CMPS) Q4 2024 Earnings Call Transcript

Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights

Feb 27, 2025, 6:30 AM EST - 7 months ago

Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 4:00 PM EST - 7 months ago

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Feb 18, 2025, 6:30 AM EST - 7 months ago

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 6:30 AM EST - 7 months ago

Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

Jan 21, 2025, 6:30 AM EST - 8 months ago

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

Compass Pathways Announces Pricing of Underwritten Offering

Jan 10, 2025, 7:01 AM EST - 8 months ago

Compass Pathways Announces Pricing of Underwritten Offering

Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)

Dec 18, 2024, 6:30 AM EST - 9 months ago

Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)

Compass Pathways to Participate in December Investor Conferences

Nov 25, 2024, 4:00 PM EST - 10 months ago

Compass Pathways to Participate in December Investor Conferences

Compass Pathways to participate in Stifel 2024 Healthcare Conference

Nov 14, 2024, 7:44 AM EST - 10 months ago

Compass Pathways to participate in Stifel 2024 Healthcare Conference

Top 3 Health Care Stocks You'll Regret Missing In November

Nov 5, 2024, 6:58 AM EST - 11 months ago

Top 3 Health Care Stocks You'll Regret Missing In November

PACS SGHT

Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity

Nov 1, 2024, 5:10 PM EDT - 11 months ago

Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity

COMPASS Pathways plc (CMPS) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 2:49 PM EDT - 11 months ago

COMPASS Pathways plc (CMPS) Q3 2024 Earnings Call Transcript

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

Oct 31, 2024, 6:30 AM EDT - 11 months ago

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

Oct 24, 2024, 6:30 AM EDT - 11 months ago

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

Sep 23, 2024, 7:00 AM EDT - 1 year ago

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

Compass Pathways to participate in three investor conferences in September

Aug 28, 2024, 6:00 AM EDT - 1 year ago

Compass Pathways to participate in three investor conferences in September

Psychedelic Stocks: Focus On Their Cash

Aug 15, 2024, 12:30 PM EDT - 1 year ago

Psychedelic Stocks: Focus On Their Cash

MNMD

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

ATAI CYBN MNMD

COMPASS Pathways plc (CMPS) Q2 2024 Earnings Call Transcript

Aug 4, 2024, 1:22 AM EDT - 1 year ago

COMPASS Pathways plc (CMPS) Q2 2024 Earnings Call Transcript

Compass Pathways announces second quarter 2024 financial results and business highlights

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Compass Pathways announces second quarter 2024 financial results and business highlights

Compass Pathways to announce second quarter financial results on August 1, 2024

Jul 24, 2024, 7:01 AM EDT - 1 year ago

Compass Pathways to announce second quarter financial results on August 1, 2024

Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies

Jul 8, 2024, 10:11 AM EDT - 1 year ago

Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies

Tpeets101
Tpeets101 Sep. 17 at 12:24 AM
$CMPS this will ten bucks one morning when we wake up! 🚀
0 · Reply
angelinvesting369
angelinvesting369 Sep. 16 at 9:14 PM
$QNRX 💩 vs $CMPS 🍄 🍆 💦 today's antidepressants have awful side effects like WEIGHT GAIN and IMPOTENCE. Psychedelics do not. Compass is only $500M mkt cap and the only psychedelic well into phase 3 trials. Glta
0 · Reply
angelinvesting369
angelinvesting369 Sep. 16 at 9:12 PM
$QNRX is a meme vs $CMPS 🍄 which is going to disrupt the $20B antidepressants industry
0 · Reply
Ramirami43
Ramirami43 Sep. 16 at 6:26 PM
$CMPS 8 before December ☝️
0 · Reply
nikstradamus
nikstradamus Sep. 16 at 2:45 PM
$CMPS Management should be dropping good news about the meeting with the FDA soon. Let’s hope they get that voucher https://www.fda.gov/industry/commissioners-national-priority-voucher-cnpv-pilot-program?utm_campaign=pharmalittle&utm_medium=email&_hsenc=p2ANqtz-9Y-yJB_9CC7EtqGvbEGYWqczmew0Ng_s7zwvZ25D3rUbviRO0dMlj-B6uFfaXPcmevkg8BNrcvDnzDA4CCDY1TLougJg&_hsmi=380780542&utm_content=380780542&utm_source=hs_email
1 · Reply
ClownThePoet
ClownThePoet Sep. 16 at 2:42 PM
$CMPS HOW CAN U BE BEARISH
0 · Reply
ClownThePoet
ClownThePoet Sep. 16 at 2:07 PM
$CMPS
0 · Reply
angelinvesting369
angelinvesting369 Sep. 16 at 12:58 PM
$TSLA $CMPS
0 · Reply
angelinvesting369
angelinvesting369 Sep. 16 at 12:57 PM
$TSLA $CMPS 🤖 will be the biggest industry in the 🌍 and 🍄 will disrupt the $20B antidepressant industry iykyk
0 · Reply
zmanx
zmanx Sep. 16 at 5:42 AM
$CMPS all set for Q4
0 · Reply
Burn0505
Burn0505 Sep. 16 at 12:41 AM
$ATYR $CMPS
0 · Reply
ClownThePoet
ClownThePoet Sep. 16 at 12:03 AM
$ATYR bring ur bags to $CMPS
0 · Reply
FrozenFeathers
FrozenFeathers Sep. 15 at 8:19 PM
$CMPS WILL WE SEE A $20 CMPS before we see a $20 MNMD?
1 · Reply
cacci11
cacci11 Sep. 15 at 2:49 PM
$CMPS what does $TSLA have to do with anything here?
1 · Reply
thepalace2007
thepalace2007 Sep. 15 at 2:24 PM
$ATAI $CMPS $CYBN $MNMD $SPY
0 · Reply
PsychedStocks
PsychedStocks Sep. 15 at 1:16 PM
$CYBN H.C. Wainwright reiterated a Buy rating on Cybin, with a price target of $150 $CMPS $MNMD $SPY $ATAI https://www.tipranks.com/news/ratings/cybins-promising-clinical-advancements-and-strategic-positioning-justify-buy-rating-ratings
1 · Reply
angelinvesting369
angelinvesting369 Sep. 15 at 12:19 PM
$TSLA if u not 👀 at $CMPS the only psychedelic in phase 3 trials u not thinking clearly https://www.fiercebiotech.com/biotech/abbvie-tunes-gilgameshs-story-inking-12b-deal-psychedelic-program
0 · Reply
ClownThePoet
ClownThePoet Sep. 15 at 11:53 AM
$CMPS thinking of buying another 500 shares and call it total 1000.
0 · Reply
angelinvesting369
angelinvesting369 Sep. 15 at 11:29 AM
$TSLA $CMPS
0 · Reply
angelinvesting369
angelinvesting369 Sep. 15 at 11:28 AM
$TSLA $CMPS
0 · Reply
angelinvesting369
angelinvesting369 Sep. 15 at 11:27 AM
$TSLA $CMPS 🍄🍆💦🌈
0 · Reply
angelinvesting369
angelinvesting369 Sep. 15 at 12:22 AM
$TSLA $CMPS https://www.statnews.com/2025/06/23/compass-pathways-psilocybin-depression-treatment-meets-trial-goal/
0 · Reply